International Journal of Pharmaceutics 184 (1999) 73–84 Preparation and characterization of protein-loaded poly(�-caprolactone) microparticles for oral vaccine delivery by M. -a. Benoit A et al.
International Journal of Pharmaceutics 184 (1999) 73–84
Preparation and characterization of protein-loaded
poly(o-caprolactone) microparticles for oral vaccine delivery
M.-A. Benoit a,*, B. Baras b, J. Gillard a
a Uni6ersite ￿ Catholique de Lou6ain, Ecole de Pharmacie, Laboratoire de Pharmacie Gale ￿nique, Industrielle et Ofﬁcinale,
A6enue Emmanuel Mounier 73.20, 1200 Brussels, Belgium
b Institut Pasteur de Lille, Laboratoire des Relations Ho ˆte, Parasite et Strate ￿gies Vaccinales, INSERM U167,
1 rue du Professeur Calmette, F-59019 Lille Cedex, France
Received 12 November 1998; received in revised form 16 March 1999; accepted 19 March 1999
Abstract
This paper describes the conditions of preparation of poly(o-caprolactone) (PCL) microparticles with a mean size
between 5 and 10 mm, obtained by a double emulsion-solvent evaporation technique, suitable for oral vaccine
delivery. Bovine serum albumin (BSA) was used as water-soluble model antigen for encapsulation. Different
parameters inﬂuencing the microparticle size, the BSA loading and entrapment efﬁciency were investigated. Spherical,
smooth and homogeneously distributed microparticles were produced with a BSA loading and entrapment efﬁciency
reaching, respectively, 5% (w:w) and 30%. Polyacrylamide gel electrophoresis (PAGE) and isoelectric focusing (IEF)
analyses of BSA released from these particles conﬁrmed that the entrapped protein seemed to remain unaltered by the
protein encapsulation process. © 1999 Elsevier Science B.V. All rights reserved.
Keywords: Poly(o-caprolactone); Biodegradable polymers; Protein delivery system; Protein microencapsulation; Oral vaccine;
Emulsion-solvent evaporation method
1. Introduction
In studies over the past 20 years, the adjuvant
effect achieved through the association of antigens
with various polymeric microparticles has been
repeatedly demonstrated (O’Hagan, 1994). The
adjuvant effect of microparticles is thought to be
directly related to their ability to be taken up by
macrophages (Tabata and Ikada, 1990). Poly(lac-
tide) (PLA) and poly(lactide-co-glycolide) (PLG)
are the primary polymeric candidates for the de-
velopment of microparticles as vaccine because
they are biodegradable and biocompatible poly-
mers. Moreover, PLG polymers have been used in
humans for many years as suture material and as
controlled-release delivery system for peptide
drugs (Wise et al., 1979).
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The humoral adjuvant effect (production of
antibodies from different isotypes) achieved by
the entrapment of antigens in biodegradable
PLG microparticles has been demonstrated only
relatively recently (Eldridge et al., 1991;
O’Hagan et al., 1991). Recent studies in mice
have shown that microparticles also exert an
adjuvant effect for cell-mediated immunity, in-
cluding the induction of a cytotoxic T
lymphocyte (CTL) response against ovalbumin
or gp120 from HIV-1 following both systemic
and mucosal administration (Maloy et al., 1994;
Moore et al., 1995). A delayed-type hypersensi-
tivity (DTH) response and potent T-cell prolif-
erative responses against ovalbumin were also
elicited following oral immunization with these
particulate carriers (Maloy et al., 1994).
Even if microparticles with adsorbed antigens
were also effective adjuvants (O’Hagan et al.,
1993b), the entrapment of the antigen within
the macroparticles should allow to use them as
controlled-release delivery systems with the po-
tential for the development of single-dose vac-
cines.
However, one major drawback of these poly-
mers is that their degradation generates extreme
acid environment (pH 2–3) in which many
antigens are found to lose their structural in-
tegrity and antigenicity (Gander et al., 1993;
Schwendeman et al., 1996).
Poly(o-caprolactone) (PCL) is an other bio-
compatible and biodegradable polyester polymer
that degrades slowly and does not generate an
acid environment unlike the PLA:PLG poly-
mers. Although the permeability of macro-
molecules in PCL is low, such low permeability
may be sufﬁcient enough for protein delivery
(Pitt, 1990). Other advantages of PCL includes
its hydrophobicity, its in vitro stability and its
low cost. Moreover, this polymer has been un-
der clinical evaluation for sustained delivery of
levonorgestrel worldwide (Pitt, 1990), and a
preliminary study performed by Jameela et al.
(1996) has demonstrated that speciﬁc humoral
immune responses (production of IgG antibod-
ies) were elicited in rats following intramuscular
administration of BSA-loaded microspheres sus-
pended in Freund incomplete adjuvant.
The administration of vaccines via a mucosal
route (oral, intranasal, intrarectal and inhala-
tion) offers several signiﬁcant advantages over
the traditional approach to vaccine delivery.
These advantages include easier administration,
reduced side effects, the potential for frequent
boosting without the need of trained personnel
and the induction of mucosal immunity at the
site of initial infection.
Particle size was shown to be an important
parameter affecting immunogenicity, because
smaller microparticles (B10 mm) were signiﬁ-
cantly more immunogenic than larger particles
(\10 mm; Eldridge et al., 1991; O’Hagan et
al., 1991). Although the factors controlling the
particle uptake across the gastrointestinal tract
are poorly deﬁned, some studies have shown
that, in order to be taken up by M cells of the
Peyer’s patches after oral administration, the
microparticles must have a diameter less than
10 mm (Eldridge et al., 1990).
The objectives of the current investigations
were to optimize a particle preparation process,
ﬁrstly described by Jeffery et al., (1993) to pro-
duce PLG microparticles, based on a double
emulsion-solvent evaporation method (water-in-
oil-in-water method, w:o:w; Jeffery et al., 1991),
to produce PCL particles with entrapped
protein having a size and size distribution po-
tentially suitable for oral delivery of antigens
and particle uptake across the gastro-intestinal
tract (i.e. between 5 and 10 mm).
We describe here the effect of processing
conditions on the particle size, protein loading
and efﬁciency of entrapment as well as the
eventual modiﬁcation on the release rate of a
water-soluble model antigen (Bovine Serum Al-
bumin) following incubation in gastric condi-
tions. The effect of the microparticle
preparative process on BSA integrity was also
investigated by polyacrylamide gel electrophore-
sis (PAGE) and isoelectric focusing (IEF) to
ﬁnally provide design and formulation guideli-
nes for delivery systems for oral vaccines based
on resorbable microparticles.M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 75
2. Materials and methods
2.1. Materials
Poly(o-caprolactone) (44000 MW) and
polyvinyl alcohol (PVA) (13–23 K, 87–89% hy-
drolyzed) were supplied by Aldrich (Bornem, Bel-
gium). Dichloromethane, chloroform and acetone
(reagent grade) were supplied by UCB (Braine
L’Alleud, Belgium). Sodium dodecyl sulphate
(SDS) was purchased from Sigma (St. Louis, MO,
USA). Low molecular weight markers (range
from 14 to 94 kDa) and isoelectric point markers
(broad pI kit range from pH 3.50 to 9.50) were,
respectively, supplied by Bio-Rad (Nazareth, Bel-
gium) and Pharmacia Biotech (Uppsala, Sweden).
Ampholine PAG plate pH range 3.5–9.5 was
supplied by Pharmacia Biotech (Uppsala, Swe-
den). Albumin (from bovine serum, fraction V)
(BSA), Folin–Ciolcateu’s phenol reagent, b-mer-
captoethanol and other materials (reagent grade)
were supplied by Merck (Darmstadt, Germany).
Other chemicals were reagent grade and used as
supplied.
2.2. Formulation of PCL microparticles with
entrapped protein
A solution of BSA (1 ml containing 188 mg) in
ultra-pure water (internal aqueous phase) was
emulsiﬁed with a 6% (w:v) solution of PCL (10
ml) in dichloromethane (DCM; oil phase) using
an Ultraturrax model T25 (IKA Laboratory
Technology, Staufen, Germany) at high speed
(8000 rpm) and room temperature. The resulting
water-in-oil (w:o) emulsion (2.5 ml) was then
emulsiﬁed with a 5% (w:v) PVA solution (50 ml)
in the same conditions that for the ﬁrst emulsion
to produce a water-in-oil-in-water (w:o:w) emul-
sion. The latter was then stirring magnetically at
9800 rpm (magnetic stirrer EOA 9 basic IKA-
MAG, IKA Laboratory Technology, Staufen,
Germany) overnight at room temperature and
pressure, to allow the evaporation of the organic
solvent and the formation of microparticles. Once
their wall was hardened, the microparticles were
collected by centrifugation (10 min at 4000g),
washed three times with 10 ml of ultra-pure water
and freeze-dried.
In these studies, the effects of the following
formulation variables on microparticle size were
investigated:
1. Concentration of the polymer solution: this
was investigated by variation in the weight of
polymer dissolved in a ﬁxed volume of DCM
(200, 400, 500 or 600 mg PCL in 10 ml DCM).
2. Effect of protein:polymer ratio: microparticles
were prepared with a range of BSA:PCL ratios
(1:24, 1:6o r1 :3), by increasing the initial
weight of BSA dissolved in the internal
aqueous phase.
3. Nature and concentration of emulsion stabi-
lizer in the external aqueous phase: while
maintaining a constant volume for the external
aqueous phase (50 ml), microparticles were
produced using various stabilizers (PVA, SDS
or Tween 80) at various concentrations (0.5, 1,
5 or 10%, w:v).
4. Viscosity of the internal aqueous phase: the
viscosity was modiﬁed by adding PVA in vari-
ous concentrations (1, 2 or 5%, w:v) in the
BSA solution.
5. Volume of the external aqueous phase: this
was studied by variation in the volume of the
second aqueous phase (10, 20 or 50 ml) while
the PVA concentration was maintained at 5%
(w:v).
6. Duration of agitation during emulsiﬁcations
(2, 5 or 15 min at 8000 rpm).
7. pH (3, 7 or 10) of the internal aqueous phase.
8. Presence of salts (NaCl) in the internal
aqueous phase.
2.3. Microparticle characterization
2.3.1. Morphology
The shape and surface texture of microparticles
were determined with a Hitashi S-570 scanning
electron microscope. A small amount of mi-
croparticles was suspended in ultra-pure water.
A drop of the suspension obtained was placed
on the sample holder, dried and observed after
coating with gold-palladium under an argon
atmosphere.M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 76
2.3.2. Particle size distribution
The microparticles sonicated for 30 s at 50–70
Watts (Soniﬁer B-12, Branson Sonic Power Com-
pany) and dispersed in ﬁltered (0.1 mm) saline
solution of 0.9% (w:v) NaCl were sized by em-
ploying a Coulter Multisizer (Coulter Electronics
Ltd., Luton, UK) equipped with a sieve of 100
mm aperture and under continuous stirring. The
results obtained from measurements of at least
three batches of microparticles are described in
volumetric mean diameter of the microparticles
(VMD) in micrometers9SEM which is the di-
ameter that divides the volume distribution curve
of the sampled microparticles in two equal parts.
2.3.3. Determination of the BSA entrapment
Estimation of the BSA content was carried out
after alkaline hydrolysis of the polymer using
NaOH and extraction by SDS as previously de-
scribed (Hora et al., 1990). Brieﬂy, 30–50 mg of
microparticles, accurately weighted, were shaken
with 3.0 ml of 1 M NaOH containing 5% (w:v)
SDS during 24 h at room temperature. The super-
natant obtained by centrifugation (4000g for 10
min at room temperature), was analyzed by
Lowry’s method of protein assay after making
background corrections for PVA (Lowry et al.,
1951). The percentage (w:w) of protein entrapped
per dry weight of microparticles was determined.
The percentage of entrapment efﬁciency was ex-
pressed by relating the actual protein entrapment
to the theoretical protein entrapment as previ-
ously described (Jeffery et al., 1993). Each sample
was assayed in triplicate.
2.4. In 6itro release of BSA
In vitro release of BSA from microparticles
(500 mg) was measured after a preincubation step
f o r2ha t37°C under gentle agitation in screw-
capped vials containing 3 ml of phosphate buffer
(0.01 M phosphate buffered saline; NaCl 0.138 M;
KCl 0.0027 M, pH 7.4) or artiﬁcial gastric
medium (7 ml HCl (36.5%, w:w), 3.2 g pepsin (0.6
U:mg) and 2.0 g NaCl for1lo fwater, pH 1.2)
(USP XXII:NFXVIII). Each medium also con-
tained 0.1% (w:v) sodium azide as bacteriostatic
agent. After neutralization of the pepsin activity
by addition of 0.1 N perchloric acid and elimina-
tion of the surrounding media by centrifugation
(4000g, 10 min), the microparticles were
washed three times with 10 ml of PBS and incu-
bated again in 5 ml of PBS to evaluate the BSA
release. In order to overcome the interference due
to PVA in protein estimations, blanks containing
500 mg of placebo microparticles were also incu-
bated as controls. At deﬁnite time intervals, the
content of vials (5 ml) was totally withdrawn by
centrifugation (4000g, 10 min) and replaced by
the same volume of fresh medium. The amount of
released BSA was estimated by Lowry’s method
(Lowry et al., 1951).
2.5. Molecular weight and isoelectric point of the
entrapped BSA
PAGE analysis of untreated BSA and BSA
released from PCL microparticles was undertaken
following the method described by Laemmli
(1970) by using the HOEFER electrophoresis Cell
SE 600 Series (Pharmacia Biotech, Uppsala, Swe-
den). Samples of BSA released from PCL mi-
croparticles in ultra-pure water, untreated BSA
and a molecular weight reference marker (molecu-
lar weight 14–94 kDa) were solubilized with sam-
ple buffer containing SDS and a reducing agent
(b-mercaptoethanol), loaded onto a vertical slab
gel (10%), and subjected to electrophoresis at 45
mA. The proteins separated by this way were
ﬁxed and stained with Coomassie brilliant blue R
250 (0.1%, w:v) in water:acetic acid:methanol
(50:10:40). The gel was ﬁnally dried by using a gel
dryer model 583 from Bio-Rad (Nazareth,
Belgium).
Retention of the isoelectric point was assessed
by IEF by using an Ampholine
® PAG plate pre-
cast polyacrylamide gel (pH 3.5–9.5) with the
Multiphor II electrophoresis unit from Pharmacia
Biotech (Uppsala, Sweden). Samples of BSA re-
leased from PCL microparticles in ultra-pure wa-
ter, unencapsulated BSA and isoelectric point
markers (pI 3.50–9.30) were applied on the sur-
face of the gel and focused at the following run-
ning conditions (1500 Volts, 50 mA, 30 W for 1.5
h at 10°C).M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 77
Fig. 1. Scanning electron micrograph of PCL microparticles
entrapping BSA produced by the standard double emulsion-
solvent evaporation method (Scale bar5 mm).
3.2. Concentration of the polymer solution
BSA loaded microparticles were prepared using
different concentrations of PCL (from 0.5 to 6%,
w:v) by variation in the weight of polymer dis-
solved in dichloromethane to investigate the even-
tual modiﬁcations of the particle size, protein
loading and efﬁciency of entrapment (Table 1).
Increasing the concentration (weight) of poly-
mer in a ﬁxed volume of organic solvent resulted
in an increase in mean particle size by at least a
factor of 2.7 and in an improvement of the
protein entrapment efﬁciency and BSA loading,
respectively, by a factor of 20 and 5 when a 5%
(w:v) polymer solution was used. This is in agree-
ment with the ﬁndings of Jeffery et al. (1991),
suggesting that the higher concentration of poly-
mer in the sample may have led to an increased
frequency of collisions, resulting in fusion of semi-
formed particles and producing ﬁnally an overall
increase in the size of the microparticles. Never-
theless, a monomodal size distribution was main-
tain (data not shown). Moreover, the high
concentration of polymer in the emulsion droplets
led to an enhancement of the efﬁciency of protein
entrapment because the high viscosity of the or-
ganic phase tends to restrict migration of the
inner aqueous:protein phase to the external water
phase (Rafati et al., 1997). Finally, at high poly-
mer concentration (6%, w:v), the viscosity was so
high that the efﬁciency of emulsion stirring was
reduced and allowed the production of large par-
ticles (5.8890.74 mm in mean diameter) with a
reduced entrapment efﬁciency (3.9690.31%).
Whatever the initial concentration of the poly-
mer solution, the entrapment efﬁciency of BSA
3. Results and discussion
3.1. Microparticles morphology
Fig. 1 displays a representative SEM mi-
crograph of PCL microparticles 2.790.07 mmi n
diameter containing 2.5391.03% (w:w) BSA ob-
tained in standard conditions mentioned in Sec-
tion 2. The particles appeared to be spherical,
smooth and homogeneously distributed without
evidence of collapsed particles.
Table 1
Effect of the polymer concentration
Polymer concentration 90% of the volume5 BSA loading (%, w:w) Mean size (mm) Entrapment efﬁciency (%)
(mm) (%)
12.2490.75 0.9890.09 0.5 1.5690.17 2.1291.02
1.0390.14 14.9591.22 2.5691.24 3.5490.21 1
2.7390.62 9.7591.68 3 1.4490.24 4.2590.32
4.3390.52 30.2995.01 12.4590.97 5 5.5291.12
5.8890.74 3.9690.31 10.9290.90 6 1.3890.11M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 78
Table 2
Effect of protein:polymer ratio
Mean size (mm) Weight of BSA (mg; ratio BSA:poly- 90% of the vol- BSA loading (%, w: Entrapment efﬁciency
ume5 (mm) mer) (%) w)
9.2291.90 25 (1:24) 1.5090.18 6.0590.96 35.9294.24
100 (1:6) 5.2690.18 7.9490.32 1.0990.22 6.5491.30
10.9290.90 1.3890.11 3.9690.31 188 (1:3) 5.8890.74
Table 3
Effect of the emulsion stabilizer type and concentration in the external aqueous phase
Concentration Mean size (mm) Stabilizer 90% of the volume5 Entrapment efﬁciency (%) BSA loading (%, w:
w) (mm) (%)
8.0990.44 PVA 15.5991.28 0.5 0.3890.02 1.2190.10
8.5190.62 16.5490.97 1 0.5190.02 1.6190.09
5 5.8890.74 10.9290.90 1.3890.11 3.9690.31
10 6.2791.74 18.3491.39 0.3190.02 0.9990.08
15.2790.40 34.1392.72 5 0.2390.01 Tween 80 0.7390.01
13.6091.14 SDS 19.6291.46 10 0.1990.02 0.7190.24
obtained in our experimental conditions was al-
ways lower than the results described by Jameela
et al. (1998) (30 vs. 60%). This difference could be
related to a difference in the crystallinity of the
polymers used. Since the crystalline phase of PCL
is essentially impermeable to water, the entrap-
ment of hydrophilic drugs likely occurs in the
amorphous regions of the polymer. Thermal
analyses (data not shown) showed that the poly-
mer selected for our studies is characterized by a
high crystalline content (\70%). Hence, the
number of amorphous domains available for the
encapsulation of hydrophilic compounds is re-
duced, allowing a low entrapment efﬁciency. On
the contrary, the entrapment efﬁciency of BSA
into microparticles from PCL (Tone polymer P-
767 Union Carbide) characterized by a low crys-
talline content (B50%) can reach 65% (data not
shown).
3.3. Effect of protein:polymer ratio
The increase of the initial weight of BSA (25,
100 or 188 mg) dissolved in the internal aqueous
phase produced a dramatic decrease in the entrap-
ment efﬁciency (87% lower) without alteration in
the microparticle size or in the BSA loading
(Table 2). It was postulated that, at high BSA
concentration (and thus at high protein:polymer
ratio), the quantity of polymer present was in-
sufﬁcient to cover the BSA completely.
3.4. Nature and concentration of emulsion
stabilizer in the external aqueous phase
Of the stabilizers studied (PVA, Tween 80 or
SDS) all resulted in successful preparation of mi-
croparticles. Nevertheless, 5% (w:v) PVA was se-
lected as stabilizer of choice for further studies,
since it allowed the preparation of particles in the
desired size range (1–10 mm) with an interesting
BSA loading (1.3890.11%, w:w; Table 3).
Except when 5% (w:v) PVA is used, it could be
shown that changes in PVA concentration were
devoided of effect on protein entrapment, particle
size and particle size distribution. The same trends
were reported by Rafati et al. (1997) for BSA-
loaded PLG microparticles when high polymer
concentrations (6%, w:v) were used. Whatever the
PVA concentration in our experimental condi-
tions, the emulsion droplets formed during agita-
tion seemed to be stable enough to harden after
solvent evaporation and form the microparticles.M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 79
3.5. Viscosity of the internal aqueous phase
Increasing viscosity of the internal phase
(Table 4) by addition of increasing concentra-
tions of PVA (1, 2 and 5%, w:v) led to a slight
increase in the particle size (from 6.4490.08 mm
without PVA to 9.6290.29 mm with 5% PVA,
w:v) with out alteration on the unimodal size
distribution. Contrary to the results obtained by
Ogawa et al. (1988) claiming that an increase in
the internal aqueous phase viscosity, which was
related to a reduction in the partitioning of the
antigen into the external aqueous phase, pro-
duced a signiﬁcant increase in ovalbumin entrap-
ment into PLG microparticles, our results
demonstrated no important effect of this parame-
ter on BSA loading and entrapment efﬁciency
when PVA solutions at 1 or 2% (w:v) were used
as described by Jeffery et al. (1993). Neverthe-
less, the use of 5% (w:v) PVA in the inner
aqueous phase was characterized by a signiﬁcant
decrease in BSA loading and entrapment efﬁ-
ciency (respectively, by a factor of 3.6 and 3.7)
which could be due to a reduction of the stirring
efﬁciency correlated to the diffusion of BSA
from the inner aqueous phase to the external
aqueous phase.
3.6. Volume of the external aqueous phase
An increase in the volume of the external
aqueous phase (from 10 to 50 ml) resulted in an
increase in both BSA entrapment (four times
higher) and microparticle size (2.5 times higher;
Table 5). A volume of 50 ml was selected as the
used volume for further studies, since it resulted
in a good entrapment efﬁciency with microparticle
size around 5 mm. The increase in particle size was
attributed to a reduction in agitation that oc-
curred because of a decrease in mixing efﬁciency
associated with larger volumes. A reduction in
mixing efﬁciency probably produced an increase
in the size of the emulsion droplets formed during
the preparative process, which would result in the
formation of large microparticles. As a result of
increased particle size, there is an associated in-
crease in particle volume, which enables more
BSA to be incorporated into the microparticles
(Jeffery et al., 1993). A linear relationship was
shown to exist between the volume of the external
aqueous phase and the amount of BSA en-
trapped. In addition, a linear relationship also
existed between the volume of the external
aqueous phase and the particle size of the mi-
croparticles produced (relationships not shown).
Table 4
Effect of PVA in the internal aqueous phase
Entrapment efﬁciency (%) Mean size (mm) 90% of the volume5 (mm) PVA concentration BSA loading (%, w:w)
(%)
6.4490.08 15.6192.35 2.6690.28 8.5190.88 0
6.8890.16 2.1590.06 11.5491.98 1 6.1290.40
2.1690.18 6.9390.56 14.2490.28 8.3590.55 2
9.6290.29 17.3590.46 0.7390.14 5 2.3290.32
Table 5
Effect of the volume of the external aqueous phase
Mean size (mm) Volume (ml) 90% of the volume5 (mm) BSA loading (%, w:w) Entrapment efﬁciency (%)
10 9.1691.53 3.2690.35 0.6990.11 2.2090.35
10.0591.94 1.3990.00 4.4490.00 20 3.0990.61
8.5190.88 2.6790.28 11.2292.98 50 7.1791.24M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 80
Table 6
Effect of the agitation duration during emulsiﬁcations
90% of the volume5 (mm) Mean size (mm) Duration (min) Entrapment efﬁciency (%) BSA loading (%, w:w)
2 4.4090.28 10.6790.35 0.6990.11 2.2190.35
5 5.0390.28 1.5790.08 6.4690.19 3.5290.57
0.4790.13 10.3390.90 1.5090.40 3.2690.35 15
3.7. Duration of agitation during emulsiﬁcations
For a constant speed of 8000 rpm, an increase
of the stirring time from 2 to 15 min resulted in a
30% reduction in microparticle size (from 4.409
0.28 to 3.2690.35 mm; Table 6). These observa-
tions could be explained by the increased shear
stresses generated in the emulsions associated to
the increase in the duration of agitation at high
homogenization rates tending to divide the
droplets of the emulsions and ﬁnally inducing a
decrease in the mean particle size. A 5-min stir-
ring time was chosen because the entrapment
efﬁciency was higher (5.0390.28%) than after 15
min (1.5090.40%).
3.8. Effect of the salts concentration and pH of
the internal aqueous phase
An increase in the internal aqueous phase pH
(from 3 to 10) induced a slight increase in the
particle size (5.5490.28 to 8.0290.90 mm) with-
out any important alteration in BSA loading or
entrapment efﬁciency (Table 7). Future studies
will be conducted with the internal aqueous phase
at pH 7.0.
If the presence of salts (NaCl 0.9%, w:v) in the
inner aqueous phase failed to modify the particle
size, it led to reduced BSA loading and entrap-
ment (by a factor of 1.6; Table 8). Future studies
will be conducted with a minimal concentration of
salts by desalting the inner aqueous phase by
using centricon concentrators (Amicon, Beverly,
USA). Nevertheless, the eventual modiﬁcations in
the release of entrapped protein following pH and
salt concentration variations related to modiﬁca-
tions in the interactions between the matrix and
protein remains to be investigated.
3.9. In 6itro release beha6ior
The protein release proﬁle of BSA-loaded mi-
Table 7
Effect of the pH of the internal aqueous phase
90% of the volume5 (mm) BSA loading (%, w:w) pH Mean size (mm) Entrapment efﬁciency (%)
1.7390.07 6.2890.23 3 5.5490.28 10.3690.46
10.4790.24 2.5390.30 7 5.8490.38 8.5891.03
8.0290.90 2.2190.44 8.0291.28 12.3690.96 10
Table 8
Effect of salts (NaCl) in the internal aqueous phase
Entrapment efﬁciency (%) 90% of the volume5 (mm) BSA loading (%, w:w) Mean size (mm) Salt concentration
(%)
2.1590.06 6.8890.16 0 6.1290.40 11.5491.98
11.8692.06 1.3790.13 0.9 4.3990.40 6.4090.65M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 81
croparticles prepared using 5% (w:v) PCL solu-
tion and 5% (w:v) PVA was investigated after a
preincubation step in gastric conditions or in PBS
(Fig. 2) in order to evaluate the suitability of these
microparticles as vaccine carriers devoted to oral
route. For both conditions of preincubation, the
release proﬁles exhibited a burst phase of protein
release in the early stages of testing amounting to
approximately 30% of the protein loading. This
ﬁrst release step was followed by a low and con-
stant rate of BSA release occurring in our in vitro
conditions for more than 3 months (data not
shown) and probably linked to the low permeabil-
ity of macromolecules in this polymer. This burst
release of protein was normally considered to be
due to the surface-located protein (Yan et al.,
1994). This phenomenon seems to be more accen-
tuated by the high hydrophobicity of the polymer,
associated to high water-soluble properties of the
entrapped molecule for which the surface situa-
tion of the entrapped protein was already demon-
strated (Benoit et al., 1997). This release proﬁle
would be especially well-adapted for vaccine re-
lease requiring a high initial dose for the priming
of immune responses and a slow continuous re- Fig. 3. Coomassie R 250-stained electrophoretic gel of BSA
released from PCL microparticles produced by the double
emulsion-solvent evaporation method. Lane 1: puriﬁed BSA (1
mg) untreated for encapsulation. Lane 2: molecular weight
markers. Lane 3: BSA (1 mg) released from particles.
Fig. 2. Protein release from BSA-loaded microparticles pre-
pared following the standard conditions and preincubated in
gastric medium or in PBS before study.
lease to induce the booster doses after a delay-
time.
3.10. Study of the structural integrity of
entrapped BSA
During microparticle preparation, the antigen
was exposed to potentially harsh conditions, such
as contact with organic solvents and mechanical
agitation. These conditions may result in irre-
versible denaturation and loss of antigenicity of
proteins. PAGE and IEF analyses followed by
Coomassie blue staining revealed identical bands
for the released and untreated BSA (Figs. 3 and
4). There were no additional bands to indicate the
presence of aggregates (molecular weight\66M.-A. Benoit et al. : International Journal of Pharmaceutics 184 (1999) 73–84 82
Fig. 4. Coomassie R 250-stained isoelectric focusing gel of
BSA released from PCL microparticles produced by the dou-
ble emulsion-solvent evaporation method. Lane 1: puriﬁed
BSA (0.8 mg) untreated for encapsulation. Lane 2: BSA (1.0
mg) released from particles. Lane 3: isoelectric point markers.
4. Conclusion
This study has demonstrated that microparti-
cles of poly(o-caprolactone) loaded with protein
may be produced by a modiﬁed w:o:w technique.
These investigations have also provided an under-
standing of the effects of some process parameters
on particle size, protein loading and entrapment
efﬁciency.
Selection of the appropriate conditions has en-
abled the preparation of smooth, spherical and
homogeneous PCL microparticles, with a mean
size of 10 mm, and without signiﬁcantly altering
the entrapped protein. The parameters were se-
lected to obtain high protein entrapment efﬁ-
ciency, with more than 30% of the initial BSA
dissolved in the internal aqueous phase being
entrapped into microparticles when a polymer
concentration of 5% (w:v) and a BSA initial
weight of 25 mg were used. High entrapment
efﬁciency is important when entrapping antigens
in relatively short supply. These formulations
would be produced with a desalted internal
aqueous phase and the volumes of the internal
and external aqueous phases, respectively, of 1
and 50 ml, with 5% (w:v) PVA as emulsion stabi-
lizer in the external aqueous phase. The two emul-
siﬁcations would be performed by stirring
emulsions 5 min at 8000 rpm.
The biodegradable property of the polymer, its
hydrophobicity and its resistance to acidic pH
make this delivery system a potential carrier for
mucosal vaccines. Within this framework, the po-
tentialities of this kind of microparticle containing
an antigen from Schistosoma mansoni as an oral
vector, and inducing a long lasting immunity fol-
lowing a single administration, were clearly
demonstrated (Benoit et al., 1998). Comparatively
to poly(lactide-co-glycolide) microparticles loaded
with the same antigen, this hydrophobic polymer
(PCL) was shown to be capable of delaying the
systemic immune responses after oral or nasal
administration (Baras et al., 1999).
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